Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech To Resubmit Avastin sBLA In Mid-2007

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is seeking substantially more information than expected from an NCI-sponsored trial for first-line treatment of metastatic breast cancer, the company says.
Advertisement

Related Content

Handicappers Debate Chances Of Genentech’s Avastin In Breast Cancer
FDA Panel To Discuss Genentech's Avastin Use In Metastatic Breast Cancer
Avastin sBLA For Metastatic Breast Cancer Gets Advisory Committee Review
Genentech Plans Avastin Breast Cancer Resubmission In August
Roche Considers Pricing Flexibility For Avastin In Europe
Genentech Alerts Of Tracheoesophageal Fistula Risk In Avastin Trial
EMEA’s CHMP Recommends Approval Of Avastin In Metastatic Breast Cancer
Genta Expects EMEA Opinion On Genasense For Melanoma In First Quarter 2007
Avastin Label Strengthened Following Leukoencephalopathy Cases
Avastin sBLA Submission Means Breast Cancer Pricing Could Be Set By November

Topics

Advertisement
UsernamePublicRestriction

Register

PS064834

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel